StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.4
Power Rank trend -> Rising
07/26/2024 16:00:00 EST
Vertex Pharmaceuticals Inc (VRTX)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, VRTX has been trading in a range between $495.91 and $468.72 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
VRTX is trading below resistance at $495.91, about 0% to the upside. There is support at $446.88 -10% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Vertex Pharmaceuticals Inc $VRTX entered a Green zone 56 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $388.67, a potential down side of -21.52% from the recent price of 495.26. The stock is trading 1.76% (potential upside) below its 52 week high of $503.99 and 45.58 % (potential downside) above its 52 week low of $340.20 - based on the recent price.
Company Summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
News
| Is Vertex Pharmaceuticals' Monopoly in Danger? Vertex's dominance in the cystic fibrosis drug market could be challenged. Even in the worst-case scenario, its challenger's products won't be launched soon. Source: The Motley Fool Thu, 25 Jul 2024 08:15:00 -0400 Sentiment: Negative |
| 3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Source: The Motley Fool Thu, 25 Jul 2024 04:10:00 -0400 Sentiment: Positive |
| Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $490.80, denoting a +0.1% change from the preceding trading day. Source: Zacks Investment Research Wed, 24 Jul 2024 18:56:09 -0400 Sentiment: Neutral |
| Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Source: Zacks Investment Research Wed, 24 Jul 2024 10:03:24 -0400 Sentiment: Positive |
| 7 Biotech Stocks to Keep on Your Clinical Radar Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true. Source: InvestorPlace Tue, 23 Jul 2024 14:57:01 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 503.99 52 Week Low: 340.2 Beta: 0.392 50 Day MA: 471.4214 200 Day MA: 416.955 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.565 Qtr Revenue Growth YOY: 0.133 Forward PE: 24.3309 Trailing PE: 31.9442